Trial Profile
A Phase 2a, Dose-Escalation, Open-Label Study to Evaluate the Safety, Tolerability, and Activity of KD025 in Subjects With Chronic Graft Versus Host Disease
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 03 Jul 2023
Price :
$35
*
At a glance
- Drugs Belumosudil (Primary)
- Indications Graft-versus-host disease
- Focus Adverse reactions; Therapeutic Use
- Sponsors Kadmon Corporation
- 01 Oct 2022 Results of pooled analysis published in the Transplantation and Cellular Therapy
- 20 May 2022 Status changed from active, no longer recruiting to completed.
- 21 Apr 2022 According to a Sanofi Media Release, the pooled analysis of two studies (KD025-208 and ROCKstar) patient-reported outcomes correlated with clinical response will be presented at the 2022 American Society for Transplantation and Cellular Therapy (ASTCT) and the Center for International Blood & Marrow Transplant Research (CIBMTR) Tandem Meetings.